Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

This is a study of tirzepatide in participants with obesity or overweight. The main purpose is to learn more about how tirzepatide maintains body weight loss. The study has two phases: a lead-in phase in which all participants take tirzepatide and a treatment phase in which participants will either continue tirzepatide or switch to placebo.

This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight.

Evaluate the effectiveness of diabetes management with Eversense CGM system non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or type 2 diabetes.

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in people with type 2 diabetes.

In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period and a 26-week Double-Blind Treatment Extension Period.

This is a study of LY900014 in participants with Type 2 Diabetes using Continuous Glucose Monitoring.

This trial compares the efficacy and safety of tirzepatide once weekly at either 5 mg, 10 mg, 15 mg dose to 3 times a day Lispro in patients with type 2 diabetes on glargine.

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.